USPTO Examiner SAWYER JENNIFER C - Art Unit 1691

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18860494PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVESOctober 2024February 2025Allow400NoNo
18857747Method for Preparing Trifluoromethyl Aromatic CompoundOctober 2024June 2025Allow800YesNo
18663548IODINATED COMPOUNDS HAVING RADIOCONTRAST PROPERTIESMay 2024December 2025Allow1911NoNo
18656138STYRYL CARBOXYLATE DERIVATIVESMay 2024January 2026Abandon2111NoNo
18656402STYRYL CARBOXYLATE DERIVATIVESMay 2024February 2026Allow2111NoNo
18438965ALL-AROMATIC LIQUID-CRYSTALLINE HOMO-POLYIMIDES WITH AROMATIC ENDGROUPS AND CROSSLINKED PRODUCTS THEREFROMFebruary 2024April 2025Allow1400YesNo
18435857DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORSFebruary 2024February 2025Allow1300NoNo
18428938PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATEJanuary 2024June 2025Allow1611NoNo
18566281METHOD FOR OBTAINING BIO-SOURCED N-VINYLFORMAMIDEDecember 2023December 2024Allow1210YesNo
18498102NON-PEPTIDIC CELL-PENETRATING MOTIFSOctober 2023March 2025Allow1611YesNo
18476222LONG CHAIN ALKYL ESTERAMINE LIPID COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN NUCLEIC ACID DELIVERYSeptember 2023March 2025Allow1721YesNo
18233769Carbondisulfide Derived ZwitterionsAugust 2023September 2024Allow1311YesNo
18253311SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDSMay 2023February 2026Allow3301YesNo
18196992DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTIONMay 2023September 2025Abandon2810NoNo
18245683BENZALDEHYDE OXIMES AND METHOD FOR PRODUCING SAMEMarch 2023January 2026Allow3410NoNo
18176862PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONISTMarch 2023April 2025Allow2502YesNo
18109702NOVEL AMINO ACID DERIVATIVESFebruary 2023March 2026Abandon3701NoNo
18041529CONTINUOUS SYNTHESIS METHOD OF 2-ACETAMIDO-5-NITROANISOLEFebruary 2023November 2025Allow3310YesNo
18041065UREA DERIVATIVES AND THEIR USE AS CURATIVES AND CURATIVE ACCELERATORS FOR RESIN SYSTEMSFebruary 2023January 2026Allow3511NoNo
18102727SYNTHESIS OF (R)(+)-2-(4-CHLORO-2-METHYL PHENOXY)PROPANOIC ACID IN HIGH ENANTIOMERIC EXCESSJanuary 2023November 2024Allow2220YesNo
18098925CRYSTALLINE FORMS OF DELTAMETHRIN AND METHODS OF USE THEREOFJanuary 2023July 2025Abandon3011NoNo
18004261METHOD FOR PRODUCING AROMATIC AMINOMETHYLJanuary 2023February 2025Allow2500NoNo
18088447Methods and Compositions for Targeting Tregs using CCR8 InhibitorsDecember 2022December 2025Allow3510YesNo
18000646CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHODDecember 2022February 2026Allow3801NoNo
18007639MOLECULAR TETRAHEDRON NANOCAGE, ITS PREPARATION, AND USES THEREOFDecember 2022September 2025Allow3400YesNo
17998738CO-PRODUCTION OF MONOMERS, INCLUDING AT LEAST ONE BIO-BASED MONOMERNovember 2022January 2025Allow2600NoNo
17921206PREPARATION OF AROMATIC CARBOXYAMIDES BY PALLADIUM-CATALYZED CARBONYLATION REACTIONOctober 2022February 2026Allow3911NoNo
17962665PROCESS FOR THE PREPARATION OF 1,3-BIS(ALLYLAMINO)PROPANEOctober 2022December 2025Abandon3910NoNo
17907512PROCESS FOR PREPARING TRIENTINE DIHYDROCHLORIDESeptember 2022December 2025Abandon3910NoNo
17913175PROCESS FOR THE PREPARATION OF HEXAMETHYLENEDIAMINE BY HYDROGENATION OF ADIPONITRILE WITH REDUCED FORMATION OF DIAMINOCYCLOHEXANESeptember 2022May 2025Allow3200YesNo
17913177PROCESS FOR THE PREPARATION OF HEXAMETHYLENEDIAMINE BY HYDROGENATION OF ADIPONITRILE IN THE PRESENCE OF RANEY NICKEL AND A BASIC CO-CATALYSTSeptember 2022January 2026Allow4010YesNo
17906603MEMBRANE SEPARATION PROCESS FOR SEPARATING CARBONATE-CONTAINING DIAMINOALKANE SOLUTIONSeptember 2022July 2025Allow3400YesNo
17911647COMPOUND, PHOTOSENSITIZER COMPRISING SAME, COMPOSITION FOR DIAGNOSING OR TREATING TUMOR TARGETING MITOCHONDRIA, AND PHOTODYNAMIC TREATMENT METHOD USING COMPOSITIONSeptember 2022January 2026Abandon4001NoNo
17941017Spacered Urea (Meth)AcrylatesSeptember 2022April 2025Allow3131YesNo
17802171PROCESS FOR ISOLATING 2-(4'-DIETHYLAMINO-2'-HYDROXYBENZOYL)BENZOIC ACID HEXYL ESTERAugust 2022December 2025Allow4010YesNo
17904964A PROCESS FOR SYNTHESIS OF HIGH PURITY l-[3-(TRIFLUOROMETHYL)PHENYL]ETHANONE OXIMEAugust 2022September 2025Allow3710YesNo
17787817PROCESS FOR THE SYNTHESIS OF TWIN-TAIL TRIAMINESJune 2022January 2026Allow4311NoNo
17783280SEPARATION OF N-METHYLETHYLENEDIAMINE FROM EDA-CONTAINING MIXTURESJune 2022April 2025Allow3500YesNo
17781405PROCESS FOR THE PURIFICATION OF A MIXTURE COMPRISING N-ALKYL-HYDROXYLAMMONIUM SALTSJune 2022May 2025Allow3500YesNo
17766615PRODUCTION OF AROMATIC ACIDS AND PHENOLICSApril 2022April 2025Allow3700YesNo
17754104METHOD FOR PREPARING FORMAMIDE COMPOUNDS VIA HYDROGENATION OF CARBON DIOXIDE CATALYZED BY POROUS MATERIALSMarch 2022March 2025Allow3600YesNo
17629840Preparation Method for Metformin HydrochlorideJanuary 2022July 2025Allow4211YesNo
17626648PROCESS FOR THE PREPARATION OF A METASTABLE CRYSTAL MODIFICATION OF N-(AMINOIMINOMETHYL)-2-AMINOETHANOIC ACID (IV)January 2022March 2025Allow3800NoNo
17617503GAS-PHASE PROCESS FOR THE CONVERSION OF GLYCOLALDEHYDE WITH AN AMINATING AGENTDecember 2021June 2025Allow4210YesNo
17609868PROCESS FOR THE SYNTHESIS OF THE IONIC LIQUID TETRAOCTYLAMMONIUM DI(2-ETHYLHEXYL)-OXAMATE (IL-5), PRODUCT OBTAINED AND ITS USE IN SELECTIVE METAL EXTRACTIONNovember 2021May 2025Abandon4301NoNo
17607656AMINE-INITIATED POLYOLS AS NON-EMISSIVE CATALYSTS IN HR FOAMOctober 2021April 2025Abandon4101NoNo
17603019PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVESOctober 2021January 2025Allow3901YesNo
17598521SYNTHESIS METHOD AND APPLICATION OF METFORMIN HYDROCHLORIDESeptember 2021September 2025Abandon4700YesNo
17477666STRUCTURE OF ADJUSTABLE STERIC HINDRANCE WEAK BASIC LIGHT STABILIZER AND PREPARATION METHOD AND APPLICATION THEREOFSeptember 2021April 2025Abandon4321YesNo
17424454METHOD FOR PREPARING SODIUM TAURATE AS TAURINE INTERMEDIATE, AND METHOD FOR PREPARING TAURINEJuly 2021January 2025Allow4101YesNo
17423247USE OF N-BENZYLBENZAMIDE-BASED COMPOUND AS HERBICIDEJuly 2021June 2025Abandon4720NoNo
17422415HERBICIDAL SUBSTITUTED N-TETRAZOLYL ARYL CARBOXAMIDESJuly 2021August 2025Allow4921YesNo
17293838ISOTOPE LABELING FOR UNIVERSAL MULTIPLEXING OF METABOLITESMay 2021May 2025Abandon4821NoNo
17314748SUBSTITUTED GUANIDINO AND AMIDINO REAGENTS AND THE USE THEREOF FOR PROTEIN DENATURATIONMay 2021September 2025Abandon5221NoYes
17291353ENANTIOSELECTIVE PROCESSMay 2021August 2025Allow5221YesNo
17291122HYDROGENATION PROCESS OF OXIME DERIVATIVESMay 2021August 2025Allow5121YesNo
17300107PROCESS FOR MANUFACTURE OF AMANTADINE NITRATE DERIVATIVESMarch 2021November 2025Allow5631NoNo
17269059COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUNDFebruary 2021November 2025Abandon5721NoNo
17258842STABLE ALKALI AMIDE SOLUTIONS AND PROCESSES FOR PREPARING SAMEJanuary 2021October 2025Allow5721NoNo
17073367Novel Mining CollectorsOctober 2020March 2024Abandon4121YesNo
16613049CLASS A GPCR-BINDING COMPOUND MODIFIERNovember 2019February 2025Allow6042YesNo
15852922AMINE SALTS OF A PROSTACYCLIN ANALOGDecember 2017August 2018Allow800NoNo
13619774FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATIONSeptember 2012December 2013Allow1500YesNo
13561039FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASEJuly 2012February 2013Allow601NoNo
13555023NOVEL BIS(FORMYLPHENYL) COMPOUND AND NOVEL POLYNUCLEAR POLYPHENOL COMPOUND DERIVED FROM THE SAMEJuly 2012June 2013Allow1101YesNo
13442401PROCESS FOR PREPARING ISOCYANATESApril 2012February 2014Allow2330YesNo
13358729PHENOXY SUBSTITUTED PHENYLAMIDINE DERIVATIVES AND THEIR USE AS FUNGICIDESJanuary 2012January 2013Allow1211NoNo
13243592FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASESeptember 2011May 2012Allow701NoNo
13069239FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATIONMarch 2011February 2013Allow2311YesNo
13048644PROCESS FOR PRODUCTION OF TEREPHTHALIC ACIDMarch 2011April 2012Allow1310NoNo
13048537PROCESS FOR PRODUCTION OF ISOPHTHALIC ACIDMarch 2011April 2012Allow1310NoNo
13035637FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATIONFebruary 2011July 2012Allow1711YesNo
13058338FLUORIDATION OF IODONIUM SALTSFebruary 2011February 2013Allow2401YesNo
12936608BIS-AROMATIC ANTICANCER AGENTSNovember 2010November 2013Allow3701YesNo
12905927SITE-SPECIFIC INHIBITORS OF HISTONE METHYLTRANSFERASE (HMTASE) AND PROCESS OF PREPARATION THEREOFOctober 2010March 2011Allow500NoNo
12922285NOVEL DIAMANTANE COMPOUNDS, LIQUID CRYSTALLINE COMPOUNDS, AND LIQUID CRYSTALLINE COMPOSITIONSOctober 2010August 2013Allow3511YesNo
12810300Process for the Synthesis of Propargylated Aminoindan DerivativesSeptember 2010February 2013Allow3201NoNo
12920224METAL CARBAMATES FORMED FROM TOLYLENEDIAMINESAugust 2010March 2013Allow3011NoNo
12918931METAL CARBAMATES FORMED FROM DIAMINOPHENYLMETHANEAugust 2010April 2013Allow3211YesNo
12746469METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAMEAugust 2010December 2012Allow3001NoNo
12599624NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICSJune 2010January 2012Allow2611NoNo
12800795LOW ODOUR OLIGOMERIC PHOTOINITIATOR AND METHOD OF MAKING THE SAMEMay 2010August 2011Allow1420NoNo
12739606Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The SameApril 2010December 2012Allow3201NoNo
11921972PRODUCTION OF N-ARYL CARBAMATES AND N-ARYL ISOCYANATESApril 2010July 2011Allow4310NoNo
12750336PHENYL-SUBSTITUTED BICYCLOOCTANE-1,3-DIONE DERIVATIVESMarch 2010August 2012Allow2901NoNo
12680852METHODS FOR THE SYNTHESIS OF ORGANIC SULFIDES BY USING SULFIDES AND ORGANIC SULFUR-INDIUM COMPLEXESMarch 2010February 2013Allow3511NoNo
12678698UV ABSORBING COMPOUNDSMarch 2010July 2012Allow2801YesNo
12678612COMPOUNDS ISOLATED FROM ANTRODIA CINNAMOMEA AND USE THEREOFMarch 2010September 2011Allow1810NoNo
12733711N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEMarch 2010September 2011Allow1811NoNo
12672416SALTS OF TRAMADOL AND NAPROXEN AND THEIR CRYSTAL FORMS IN THE TREATMENT OF PAINMarch 2010February 2012Allow2421NoNo
12733479AMPHIPHILIC OXALAMIDE ORGANOGELATORS DESIGNED FOR GELATION OF ORGANIC SOLVENTS, WATER AND HYDROCARBON COMMERCIAL FUELSMarch 2010September 2013Allow4321YesNo
12530007INSECTICIDAL COMPOUNDSJanuary 2010April 2012Allow3221NoYes
12670294IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROLJanuary 2010August 2012Allow3101YesNo
12651142PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERSDecember 2009April 2013Allow3921YesNo
12651268PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS AND COMPOSITIONSDecember 2009September 2013Allow4521YesNo
12633944CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUNDDecember 2009September 2011Allow2211NoNo
12592318MULTIFUNCTIONAL ANIONIC SURFACTANTSNovember 2009November 2010Allow1200NoNo
12600515NOVEL METHOD OF SYNTHESIZING FENOFIBRATENovember 2009January 2013Allow3810YesNo
12448672METHOD FOR PREPARATION OF 6-[3-(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACIDOctober 2009October 2011Allow2720NoYes
12603025COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERSOctober 2009October 2013Allow4822YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAWYER, JENNIFER C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
1.4%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
3
(75.0%)
Not Allowed After Appeal Filing
1
(25.0%)
Filing Benefit Percentile
93.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 75.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SAWYER, JENNIFER C - Prosecution Strategy Guide

Executive Summary

Examiner SAWYER, JENNIFER C works in Art Unit 1691 and has examined 121 patent applications in our dataset. With an allowance rate of 92.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner SAWYER, JENNIFER C's allowance rate of 92.6% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SAWYER, JENNIFER C receive 1.07 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SAWYER, JENNIFER C is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -1.0% benefit to allowance rate for applications examined by SAWYER, JENNIFER C. This interview benefit is in the 10% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 45.5% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 25.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.9% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.